Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)

Next Previous
Trial Profile

The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 22 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sildenafil (Primary)
  • Indications Fetal growth retardation
  • Focus Therapeutic Use
  • Acronyms STRIDER

Most Recent Events

  • 01 Jan 2024 Results of a post-hoc secondary analysis assessing differences in neonatal outcomes when comparing different corticosteroid timing strategies published in the Acta Obstetricia et Gynecologica Scandinavica
  • 01 Apr 2022 Results of a post hoc analysis assessed the neonatal pulmonary hypertension after severe early-onset fetal growth restriction published in the European Journal of Pediatrics
  • 01 Aug 2018 The trial has been discontinued in Netherlands.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top